Eric Bjerkholt

A novel oral immunotherapy developed by Aimmune Therapeutics Inc (NASDAQ: AIMT) to treat peanut allergy is on the cusp of FDA approval after a nearly nine-year-long journey from lab to shelf. Benzinga spoke to Aimmune Chief Financial Officer Eric Bjerkholt in a freewheeling chat. It'...